Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Shares of 4D Pharma (LON: DDDD) are trading lower on Friday after announcing the voluntary discontinuation of enrollment in the Phase 2 study of MRx-4DP0004 to treat hospitalised patients with COVID-19 in the UK.
The decision was made for 4D to focus on its core LBP pipeline candidates and due to the increase in vaccination rates, declining hospitalisation rates, and progress in the MRx-4DP0004 asthma clinical trial.
4D Pharma also announced the completion of its target enrollment of 30 patients for Part A of its Phase 1/2 clinical trial of MRx-4DP0004 in patients with partly controlled asthma.
Following the completion of enrollment of Part A, 4D pharma expects to announce topline results from these patients in the second half of this year.
The developer of live biotherapeutic products said MRx-4DP0004 is an oral, immunomodulatory, single strain LBP that has been shown to reduce airway inflammation in a pre-clinical model of severe asthma.
The first-in-human Phase 1/2 trial is a two-part trial of MRx-4DP0004 in patients taking long-term medication for asthma. The primary endpoint of Part A of the trial is safety and tolerability.
“The completion of enrollment in Part A of 4D pharma's asthma study is an important milestone for this program. This is expected to provide further validation of the favorable safety profile of LBPs as a novel class of drug across a wide range of indications, including respiratory disease,” said Alex Stevenson, Chief Scientific Officer, 4D pharma.
4D Pharma's share price is currently trading at 93.8p, down 2.84%.
4D Pharma shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are 4D Pharma shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .